Kidney drug tested in diabetic vs non-diabetic patients – results may guide future care
NCT ID NCT07302464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a class of diabetes drugs called SGLT2 inhibitors changes kidney function in people with chronic kidney disease (CKD). Researchers compared 60 patients with and without diabetes to see if the drug affects their estimated glomerular filtration rate (eGFR) differently. The goal was to understand whether these drugs benefit both groups, not just those with diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
Cairo, 11591, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could a phone app be the key to managing kidney disease?
- Could diabetes be silently damaging your hearing?